BTG Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BTG Plc with three other
pharmaceutical manufacturers in Europe:
Dottikon ES Holding AG
sales of 121.43 million Swiss Francs [US$120.35 million]
of which 90%
was Pharma Products),
(£171.67 million [US$209.10 million]
of which 100%
was Antibodies & Related Products), and
Dechra Pharmaceuticals PLC
(£247.56 million [US$301.54 million]
of which 76%
was European Pharmaceuticals).
BTG Plc reported sales of £447.50 million (US$545.07 million)
March of 2016.
increase of 21.7%
versus 2015, when the company's sales were £367.80 million.
Sales at BTG Plc have increased during each of the previous five years
(and since 2011, sales have increased a total of 302%).
Sales of Interventional Medicine saw an increase
33.3% in 2016, from
£112.70 million to £150.20 million.